Clinical Trial: Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 Mg (Triptorelin Mesylate Injection, 22.5 Mg) in Patients with Advanced Prostate Cancer

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06795191) titled 'Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 Mg (Triptorelin Mesylate Injection, 22.5 Mg) in Patients with Advanced Prostate Cancer' on Jan. 22.

Brief Summary: This is a study in male patients with advanced prostate cancer who are eligible for androgen ablation therapy. The study duration will be up to 48 weeks.

Eligibility will be assessed during a screening period of up to 28 days. Up to 2 doses of a long-acting FP-014, 22.5 mg formulation will be given to the patients by separate SC injections 24 weeks apart in an unblinded manner. The first dose of FP-014, 22.5 mg will be administered on Day 0 (Visit 2/Week 1). When p...